Alzheimers

Alzheimer’s disease is a progressive neurodegenerative disorder and the most common cause of dementia worldwide. Early detection and monitoring are becoming increasingly important as research advances and new treatment approaches emerge. In recent years, blood-based biomarkers associated with Alzheimer’s disease, including phosphorylated tau (p-tau217), glial fibrillary acidic protein (GFAP), amyloid beta (Aβ), and neurofilament light chain (NfL), have gained significant attention for their potential to support research, screening, and clinical decision-making.

Game-Changer for Alzheimer’s Disease Diagnostics

Recent breakthroughs in Alzheimer’s disease (AD) research have reshaped the landscape of diagnostics and treatment. At the forefront of these developments is Professor Henrik Zetterberg, Professor of Neurochemistry at the University of Gothenburg and UCL, and one of the world’s leading researchers on biomarkers for neurodegenerative dementias.

Read the full case here.

Decentralized Alzheimer’s disease biomarker research

Blood-based biomarkers are opening new opportunities for Alzheimer’s disease research by enabling less invasive approaches to study disease pathology, progression, and risk. As interest grows in earlier detection, longitudinal monitoring, and large-scale studies, accessible sampling methods are becoming increasingly important.

Remote capillary blood collection may support broader participation by allowing samples to be collected outside specialist clinical settings. Recent studies have shown that Alzheimer’s disease-related biomarkers can be measured from dried capillary blood samples, including self-collected samples returned by regular mail, while further validation is still needed before broader clinical implementation.